Eyegate Pharmaceuticals  Inc. has launched a Phase 3 clinical trial for its drug target, called EGP-437, to treat dry eye syndrome. The drug candidate is a type of steroid, delivered using the company’s proprietary, non-invasive delivery system, known as Eyegate II.
The Waltham-based privately-held biotechnology company said that its previous Phase 2 study of the potential therapy found significant improvements in the signs and symptoms of dry eye during and after exposure to adverse environmental conditions.
Stephen From, president and CEO of EyeGate Pharma, said in a statement, “Based on clinical data, we recognize the potential value that EGP-437 may offer patients. Thus, we are excited to initiate this important pivotal study, which moves the company one step closer to submitting a New Drug Application (NDA).”
The company’s pipeline of ocular disease medicines use a new drug delivery platform that involves using a small electrical charge to move drug targets more quickly to certain parts of the eye.